Update on autochthonous Plasmodium vivax malaria in Greece

Similar documents
How to design intranational deferral Malaria in Greece

EPIDEMIOLOGICAL SURVEILLANCE REPORT Malaria in Greece, 2012

HELLENIC CENTER FOR DISEASE CONTROL & PREVENTION (H.C.D.C.P) MINISTRY OF HEALTH & SOCIAL SOLIDARITY

EPIDEMIOLOGICAL SURVEILLANCE REPORT Malaria in Greece, 2018, up to 22/10/2018

EPIDEMIOLOGICAL SURVEILLANCE REPORT Malaria in Greece, 2017, up to 17/08/2017

Odyssean malaria outbreak at a bush lodge in Madikwe Game Reserve, North West Province, October-November 2015


Surveillance of malaria vectors in the Municipality of Evrotas (Laconia) & Marathonas (Attica)

Malaria DR. AFNAN YOUNIS

Malaria. Population at Risk. Infectious Disease epidemiology BMTRY 713 (Lecture 23) Epidemiology of Malaria. April 6, Selassie AW (DPHS) 1

PARASITOLOGY CASE HISTORY #14 (BLOOD PARASITES) (Lynne S. Garcia)

Emerging TTIs How Singapore secure its blood supply

Managing malaria. Scenarios. Scenario 1: Border provinces, Cambodia. Key facts. Your target region: Cambodia /Thailand border

WEEKLY EPIDEMIOLOGICAL REPORT WEST NILE VIRUS INFECTION, GREECE - 14 November

1,3,7 New Strategy for Malaria surveillance in elimination phases in China. Prof. Gao Qi

Keeping the country malaria-free is an ongoing battle

Field Data for Anopheles spp. in Greece

Alberta Health Public Health Notifiable Disease Management Guidelines July 2012

Outbreak of travel-associated Legionnaires' disease Palmanova, Mallorca (Spain), September October Main conclusions and options for response

IPM & the West Nile Virus Epidemic, Greece, Terms to Know. Which is more dangerous? Florida and Thessaloniki, Greece

Invest in the future, defeat malaria

Weekly Epidemiological Report for West Nile Virus disease, Greece, July

Lumpy skin disease (LSD) & Sheep Pox. State of play in the EU

Kato, N. et al, Nature, 2016, Accelerated Article Preview. Celeste Alverez Current Literature 9/10/ /10/2016 Celeste Wipf Group 1

MALARIA CONTROL FROM THE INDIVIDUAL TO THE COMMUNITY

Plasmodium Vivax Malaria Transmission in a Network of Villages

Road map for malaria control (and elimination): public health priorities

Page 1 of 9 13-ID ID-08. Public Health Reporting and National Notification for Malaria

Imported malaria: a possible threat to the elimination of malaria from Sri Lanka?

Malaria Situation and Plan for Elimination in China

Transmission network dynamics of Plasmodium Vivax Malaria

Malaria. Dr Zia-Ul-Ain Sabiha

Malaria Risk Areas in Thailand Border

Comparison of light microscopy and nested PCR assay in detecting of malaria mixed species infections in an endemic area of Iran

NATIONAL MALARIA ELIMINATION ACTION PLAN Ministry of Health Belize

Anti-Malaria Chemotherapy

Malaria Updates. Fe Esperanza Espino Department of Parasitology Research Institute for Tropical Medicine

Malaria. An Overview of Life-cycle, Morphology and Clinical Picture

Malaria elimination in Jiangsu China

Action Plan of China Malaria Elimination ( ) Page 2

Local Transmission of Plasmodium vivax Malaria --- Palm Beach County, Florida, 2003

Better Training for Safer Food BTSF

West Nile Virus Surveillance in mosquito vectors (Culex pipiens)

ESCMID Online Lecture Library. by author

Economic crisis and communicable diseases in Greece

Risk Assessment Centre on Food Chain Project link to the Delphi priorities / EFSA Strategy topics

Eliminating malaria in TURKEY

ASIA PACIFIC MALARIA GUIDE A QUICK REFERENCE FOR JOURNALISTS AND OTHERS INTERESTED IN MALARIA AND ITS ELIMINATION IN THE ASIA PACIFIC

WEST NILE FEVER in Greece Epidemiological Situation in 2011

European Centre for Disease Prevention and Control. Zika virus disease

Malaria screening of donors and donations - issues and outcomes

Copenhagen, Denmark, September August Malaria

Transfusion transmitted infections in National Haemovigilance Systems: the Greek experience

The Royal Veterinary College. The Swiss Federal Veterinary Office

A framework for malaria elimination. Dr Pedro Alonso, GMP Director

West Nile Virus in Maricopa County

West Nile Virus in Maricopa County

Lumpy skin disease: Scientific report

Proposed Evidence Review Group on assessment of malariogenic potential to inform elimination strategies and plans to prevent re-establishment

by author ESCMID Online Lecture Library Malaria Epidemiology, diagnosis and risk of resurgence Eskild Petersen Professor, MD, DMSc

Symptoms of Malaria. Young children, pregnant women, immunosuppressed and elderly travellers are particularly at risk of severe malaria.

EPIDEMIOLOGY OF IMPORTED MALARIA CASES IN JORDAN BETWEEN 2000 AND 2005

Media centre Malaria. Key facts. Symptoms

Weekly Epidemiological Report for the West Nile virus disease, Greece, October 2013

Global Climate Change and Mosquito-Borne Diseases

Official Journal of the European Union

Increase in temperatures in Africa, rise in humidity creating new water sources and the start of agriculture in the Middle East and North East Africa

SUMMARY AND CONCLUSION

African swine fever in the EU 13/10/16 EP

West Nile Virus in Maricopa County

Fact sheets on sustainable development goals: health targets. Malaria

COMMISSION IMPLEMENTING REGULATION (EU)

Emergence of chikungunya in Moonlapamok and Khong Districts, Champassak Province, the Lao People s Democratic Republic, May to September 2012

University of Veterinary and Animal Sciences, Bikaner), V.P.O. Bajor, Dist. Sikar, Rajasthan, India

West Nile Virus in Maricopa County

40% (90% (500 BC)

My Fellowship Achievements

Giardiasis (lambliasis)

Malaria Outbreak in District Korea, Chhattisgarh

5163/18 GSC/ar 1 DGB 2B

malaria epidemics FD90C2A80F37419F A1B6C58 Malaria Epidemics 1 / 6

UNGUNYA (Article From Nammude Arogyam) viral Virus Prevalence: Symptoms:- Epidemic in Kerala 2007:- Virological Investigations

Regional workshop on updating national strategic plans for the prevention of re-establishment of local malaria transmission in malaria-free countries

Progress on the Containment of Artemisinin Tolerant Malaria Parasites in South-East Asia (ARCE) Initiative

Mosquito Control Update. Board of County Commissioners Work Session February 16, 2016

EU measures for surveillance and control of ASF in feral pigs

Knowledge is power: 815 Second Avenue New York, NY Toll Free HEAL

European monthly measles monitoring (EMMO)

Media centre Statement on the 7th IHR Emergency Committee meeting regarding the international spread of poliovirus

Average Household Size and the Eradication of Malaria

Reducing Babesia and Malaria Risks: Testing, Donor Selection, Inactivation. Susan L. Stramer PhD IPFA 23 rd Meeting May

Counting Malaria Out: Progress of Efforts in the Americas and More Stories of Innovations. Counting Malaria Out in the Americas

Rift Valley Fever. What is Rift Valley Fever?

Climate changes and animal infectious diseases

Swaziland National Malaria Elimination Policy

Lumpy skin disease (LSD) Epidemiological situation in Europe (update since LSD4)

Eighth intercountry meeting of national malaria programme managers from HANMAT and PIAM-Net countries

West Nile Virus Surveillance Report, 2018: For week ending July 7

POSTGRADUATE INSTITUTE OF MEDICINE UNIVERSITY OF COLOMBO MD (MEDICAL PARASITOLOGY) EXAMINATION JANUARY, 2001 PAPER 1

Lumpy Skin Disease in Greece Update. Situation as at 7 October 2015)

Transcription:

RAPID RISK ASSESSMENT Update on autochthonous Plasmodium vivax malaria in Greece 11 October 2011 Main conclusions and recommendations Greece has reported thirty-six cases of Plasmodium vivax infection in 2011 to date, 20 of which have been in Greek citizens without travel history to an endemic country. Over eighty percent of these cases are associated with the area around Evrotas, located in Lakonia, in the Peloponnese region of southern Greece. This area (and four others currently reporting malaria cases) is agricultural and not usually associated with tourism. The ECDC risk, as assessed on 23 August 2011, remains unchanged. The main risk is to persons residing in, visiting and working in the affected areas of Greece, particularly Evrotas in Lakonia. The risk for further extension of malaria transmission into the EU as a result of this event is considered low at present. EU national blood competent authorities should be considering whether to implement deferral measures for persons returning from these specific affected areas in Greece, taking into consideration measures currently implemented by the Greek blood safety authorities and after a considered risk assessment in collaboration with their national public health authorities. Public health issue Cases of autochthonous malaria due to Plasmodium vivax reported in Greece. Source of assessment request and experts consulted This updated rapid risk assessment was undertaken following an internal decision at ECDC. * Erratum: In the Rapid Risk Assessment Update on autochthonous Plasmodium vivax malaria in Greece dated 5 October 2011, ECDC incorrectly referred to the distribution of malaria cases in Greek citizens and migrant workers. The correct formulation is: Greece has reported thirty-six cases of Plasmodium vivax infection in 2011 to date, 20 of which have been in Greek citizens without travel to an endemic country. This was corrected on 11 October 2011. ECDC would like to apologise for this error and any inconvenience caused. European Centre for Disease Prevention and Control, Stockholm, 2011

ECDC would like to thank the following external organisations who were consulted for this assessment update: Department of Surveillance and Intervention of the Hellenic Centre for Disease Control and Prevention (CDC), National School of Public Health, Greece and the World Health Organization (WHO). Disease background information Plasmodium vivax is one of the five main Plasmodium species that cause human malaria (P. vivax, P. falciparum, P. malariae, P. ovale and P. knowlesi). All are transmitted through the bite of female Anopheles mosquitoes. The main symptoms of malaria are cyclical fever and chills, headache, weakness, vomiting and diarrhoea. The most common complication is enlargement of the spleen. The incubation period for P. vivax usually ranges from 10 to 21 days, but can be up to a year. Unlike P. falciparum malaria, P. vivax malaria is rarely fatal. However, P. vivax relapses often occur months or even years after treatment due to the fact that the parasites can develop dormant forms (hypnozoites) in the liver. Relapses are not prevented by current chemo-prophylactic regimens, with the exception of primaquine, which should always be added to treatment regimens to eradicate dormant liver forms. Among the five Plasmodium species, P. vivax has the widest global distribution. Nevertheless, this parasite is not endemic in EU and EEA/EFTA countries. Between 2006 and 2009, the confirmed rate of malaria cases in EU and EEA/EFTA countries remained stable at around one per 100 000 population. Of those cases for whom the relevant information was available, 99.5% were imported [1]. Within the WHO European Region, autochthonous P. vivax infections are regularly reported (e.g. from eastern Turkey), although this trend is decreasing. In Spain, a case of autochthonous malaria (P. vivax) was also reported from the Aragon region in 2010 [2]. Autochthonous cases of malaria in Greece have previously been reported in 1999 and 2000 [3][4]. Following several years with no reports, six cases of autochthonous malaria were reported in 2009 (through the European Surveillance System TESSy 2009) and one in 2010, all residing in the same area of Evrotas, Lakonia, in the Peloponnese region of southern Greece [5]. The 2009 cases were associated with two imported cases of P. vivax from Pakistan and Afghanistan occurring during the summer in Evrotas. All reported cases made a full recovery. It is known that mosquito vectors for malaria are present in Greece. In the Peloponnese region, the following species have been identified: A. maculipennis s.s., A. sacharovi, A. hyrcanus and A. superpictus [6]. A. sacharovi is commonly found from May to September in wetlands and rice paddies, with the highest numbers of adult mosquitoes being observed in July. Event background information So far in 2011 (up to 26 September), 36 cases of P. vivax malaria have been reported to the Hellenic Centre for Disease Control and Prevention, and these cases are potentially autochthonous. Of the 36 cases reported, 20 occurred in Greek citizens with no travel history to a malaria endemic country. The other 16 cases were in migrant workers from Pakistan (the vast majority), Afghanistan and Morocco. Figure 1 indicates the geographical area of residence associated with these potentially autochthonous cases. Over 80% (30 cases) are reported to live around Evrotas, in the Prefecture of Lakonia, situated in the Peloponnese region of southern Greece. This is the same small geographical area where eight confirmed cases of P. vivax malaria occurred between August and October 2009 (two imported cases and six autochthonous cases) and one case in 2010. The area is largely farm land covered with citrus trees. The vast majority of farm workers are migrants from malaria-endemic areas of Asia and the Indian subcontinent, especially during the cropping season. It is reported that approximately 2 000 4 000 migrants currently live and work in the area of Skala, Lakonia and that there is a rapid turnover in their population. One case is reported to have died; a man over 70 years of age who had severe underlying medical conditions. In addition to Lakonia, four other prefectures have reported autochthonous malaria cases in Greek citizens in 2011; two cases in Evoia, two in Attiki, one in Larissa and one in Viotia. All the affected areas are non-touristic, agricultural areas in close proximity to wetlands. The first case reported disease onset on 23 May 2011 and, in the most recently reported case, disease onset occurred on 21 September 2011. Figure 2 shows the distribution of cases by week of disease onset and area of residence. The overall gender distribution among the confirmed cases is 29 males and seven females. The age distribution among reported cases ranges between 1.5 and 79 years. 2

Figure 1. Geographic area of residence in Greece of P. vivax malaria cases without travel history to an endemic country, as of 26 September 2011 Source: Hellenic CDC In addition, two Romanians are reported to have been diagnosed with P.vivax infection following their return to Romania after working and residing in the area of Skala, Lakonia. Control measures implemented by the Hellenic CDC include enhancing surveillance in the affected areas (those areas reporting cases) to rapidly identify cases; informing health care professionals about early malaria diagnosis and treatment; raising public awareness and improving blood safety. Blood safety measures implemented by Greece in the affected areas include: Suspension of blood donation sessions in the affected areas and surrounding agricultural villages within a radius of 10 km for a period of six months. (This distance criterion is based on the mosquito s flying capacity which is estimated to be about five kilometres). Temporary deferral of blood donation from asymptomatic persons residing or working in the affected areas for a period of six months. Temporary ban on blood donation from Greek citizens with family history of malaria. To prevent a negative impact on the blood supply, blood units collected in the affected areas of Lakonia and East Attica are being PCR tested in cooperation with the National School of Public Health s Reference Laboratory for Parasitic Diseases. Up until 22 September 2011, no positive blood unit had been detected. Entomological investigations in 2009 revealed the presence of A. sacharovi in the area of Evrotas. In June 2011, adult Anopheles spp. mosquitoes were not identified in CO 2 and light traps, although a limited number of Anopheles larvae were found in the wetlands. In August 2011, a small number of adult Anopheles mosquitoes were collected using the same methods and identified as Anopheles sacharovi. Intensified mosquito control measures have also been introduced by the local authorities. ECDC threat assessment for the EU Greece was historically malaria-endemic until national eradication programmes allowed the country to achieve malaria-free status in 1974. This is now the third consecutive year in which autochthonous cases have been reported in the country. The six cases reported in 2009 and thirty cases reported in 2011 are from the same 3

geographic area of Evrotas, Lakonia. A further four Greek prefectures have reported autochthonous malaria cases in Greek citizens in 2011. The transmission of P. vivax malaria in the Skala area, Evrotas may result from several mechanisms and, on the basis of the information available, it is not possible to ascertain which is responsible. These mechanisms are: - Introduction of malaria every year by migrants originating from malaria-endemic countries, resulting in subsequent onward transmission to nearby residents by local mosquito vectors; - Overwintering of parasite in local mosquito vectors, resulting in subsequent onward transmission to nearby residents by local mosquito vectors; - Established human reservoirs of P. vivax in these areas following introduction in previous years, resulting (through relapses) in subsequent onward transmission to nearby residents by local mosquito vectors. However, the increased number of autochthonous cases reported this year would indicate that conditions (vector and population) can be considered favourable for sustained local transmission in the affected areas, especially Evrotas in Lakonia, despite intensive intervention efforts for vector control. The main risk related to the current event is to persons residing, visiting and working in the affected areas of Greece, particularly that of Evrotas, Lakonia. As the risk for malaria in Greece is still considered very limited and intervention measures are ongoing in the affected areas, a general recommendation for travellers to take prophylaxis is not advised at this date. However, standard measures should be taken to prevent mosquito bites. As the mosquito season for 2011 has not yet come to end, additional cases of P.vivax may yet be diagnosed and reported from the five affected areas. Such cases may occur among residents, but also among people visiting or working in these areas from EU and non-eu countries. National authorities responsible for blood safety in EU Member States that may be considering whether to implement deferral measures [7] for persons returning from the affected areas in Greece should take into consideration the measures currently being implemented by the Greek blood safety authorities, and conduct a risk assessment for travellers returning from these areas in collaboration with their national public health authorities. The current malaria situation in Greece represents a very limited risk of spread to the rest of the European Union, compared to that of travellers returning from other malaria-affected countries worldwide. However, it is important that health practitioners in other Member States include malaria infection in the differential diagnosis in symptomatic persons returning from these areas in Greece. It is unlikely that autochthonous transmission of malaria will re-establish itself in wider continental Europe, as it is dependent upon mosquito distribution and abundance; vectorial capacity and vector competence of the mosquitoes, and the introduction of the parasite through travel by carriers of Plasmodium spp. gametocytes. Some of these factors depend on climate and environment and, although as yet no changes in species distribution of anopheline mosquitoes related to climate change have been observed in the EU, this factor cannot be excluded in the future. For this reason, it is important to continue closely monitoring the situation in areas of the European Union where Anopheles mosquito populations are present and to increase awareness among clinicians. This will ensure that suspected malaria cases are rapidly identified and reported to the respective authorities, giving rise to an appropriate public health response. Conclusions The current epidemiological and entomological evidence in Greece shows that local transmission of malaria is possible in different areas in Greece. However, the majority of reported cases are confined to a delimited geographical area in the delta of the Evrotas River in the Lakonia Prefecture of the Peloponnese, in southern Greece. The main risk is to persons residing, visiting and working in the affected areas of Greece, particularly that of Evrotas, Lakonia. All areas from which malaria cases are currently being reported are agricultural rather than touristic and located close to wetlands. The 2011 mosquito season has not yet come to an end and therefore it is possible that new cases might occur among residents and persons visiting or working in the affected areas, especially Evrotas, Lakonia. The risk for further extension of malaria transmission into the European Union in relation to this event is considered low at present. 4

References [1] European Centre for Disease Prevention and Control (ECDC). Annual Epidemiological Report 2011 (2009 data) (in press). [2] Santa-Olalla Peralta P, Vazquez-Torres MC, Latorre-Fandos E, Mairal-Claver P, Cortina-Solano P, Puy-Azon A, et al. First autochthonous malaria case due to Plasmodium vivax since eradication, Spain, October 2010. Euro Surveill. 2010 Oct 14;15(41):19684. [3] Kampen H, Maltezos E, Pagonaki M, Hunfeld KP, Maier WA, Seitz HM. Individual cases of autochthonous malaria in Evros Province, northern Greece: serological aspects. Parasitol Res. 2002 Mar;88(3):261-6. [4] Kampen H, Proft J, Etti S, Maltezos E, Pagonaki M, Maier WA, et al. Individual cases of autochthonous malaria in Evros Province, northern Greece: entomological aspects. Parasitol Res. 2003 Mar;89(4):252-8. [5] Bezirtzoglou C, Dekas K, Charvalos E. Climate changes, environment and infection: Facts, scenarios and growing awareness from the public health community within Europe. Anaerobe. 2011 Jun 2. [6] Ramsdale C, Snow K. Distribution of the genus Anopheles in Europe. European Mosquito Bulletin. 2000;7:1-26. [7] Commission Directive 2004/33/EC of 22 March 2004 implementing Directive 2002/98/EC of the European Parliament and of the Council as regards certain technical requirements for blood and blood components. Official Journal of the European Union L91/25 (30.3.2004). Available at: http://eurlex.europa.eu/lexuriserv/lexuriserv.do?uri=celex:32004l0033:en:html 5